Pfizer and Moderna Seek FDA Authorization for Pediatric Doses of New COVID-19 Boosters
Pfizer has applied for FDA authorization to allow children 5-11 years old to receive its new COVID-19 booster. The bivalent booster is already authorized for kids age 12 and older. The booster is called bivalent because protects against both the original COVID-19 virus and the newer omicron variants. Receiving the updated vaccine is critical for protecting yourself because previous versions of the vaccine are much less effective against the widely circulating omicron strains. Moderna is also seeking FDA authorization for pediatric doses of its version of the new booster, which is currently only available to adults 18 years and older.